TY - JOUR
T1 - Evaluation of adherence rates following ectopic pregnancy to inform management decisions in a public hospital system
AU - Sobecki-Rausch, Janelle
AU - Madrigal, Jessica M.
AU - Cavens, Arjeme
AU - Dahl, Carly
AU - Patel, Ashlesha
N1 - Funding Information:
None.
Publisher Copyright:
© 2021 Elsevier Masson SAS
PY - 2021/11
Y1 - 2021/11
N2 - Introduction: Adherence to follow-up is an important consideration when treating non-emergent ectopic pregnancy. Our aim was to evaluate the management of ectopic pregnancy among patients in a public hospital system and to identify factors related to adherence of medical management in this population. Material and methods: A retrospective review to evaluate the management of ectopic pregnancy among women in a public hospital system, including all women undergoing treatment for ectopic pregnancy from 2012 to 2017. Data were abstracted from the medical record. Women who were adherent to follow-up were compared to those who were non-adherent. Log-binomial regression was used to identify factors associated with management type and adherence to follow-up of medical management. Results: Of 283 women diagnosed with an ectopic pregnancy, 182 (64.3%) were managed surgically and 101 (35.7%) were managed with methotrexate. Among non-emergent cases, presence of fetal cardiac activity, human chorionic gonadotropin (HCG) level ≥5000mIU/mL, ectopic size ≥3.5 cm, and multigravid status was associated with surgical management. Among patients receiving methotrexate, 66 (65.3%) adhered to required lab draws 4 and 7 days following methotrexate administration (+/-1 day). Among those receiving methotrexate 45.5% (n = 46) were lost to follow-up. Lower prevalence of adherence to follow-up (i.e. lab draws completed until pregnancy levels were negative) was observed among non-Hispanic African American (RR=0.64, 95%CI 0.45–0.94) compared to white women and women with multigravid status (RR=0.67, 95%CI 0.48–0.95) after adjustment. Conclusions: Nearly half of those treated with methotrexate failed to complete follow-up. African-American women and multigravida women were at higher risk of being lost to follow up.
AB - Introduction: Adherence to follow-up is an important consideration when treating non-emergent ectopic pregnancy. Our aim was to evaluate the management of ectopic pregnancy among patients in a public hospital system and to identify factors related to adherence of medical management in this population. Material and methods: A retrospective review to evaluate the management of ectopic pregnancy among women in a public hospital system, including all women undergoing treatment for ectopic pregnancy from 2012 to 2017. Data were abstracted from the medical record. Women who were adherent to follow-up were compared to those who were non-adherent. Log-binomial regression was used to identify factors associated with management type and adherence to follow-up of medical management. Results: Of 283 women diagnosed with an ectopic pregnancy, 182 (64.3%) were managed surgically and 101 (35.7%) were managed with methotrexate. Among non-emergent cases, presence of fetal cardiac activity, human chorionic gonadotropin (HCG) level ≥5000mIU/mL, ectopic size ≥3.5 cm, and multigravid status was associated with surgical management. Among patients receiving methotrexate, 66 (65.3%) adhered to required lab draws 4 and 7 days following methotrexate administration (+/-1 day). Among those receiving methotrexate 45.5% (n = 46) were lost to follow-up. Lower prevalence of adherence to follow-up (i.e. lab draws completed until pregnancy levels were negative) was observed among non-Hispanic African American (RR=0.64, 95%CI 0.45–0.94) compared to white women and women with multigravid status (RR=0.67, 95%CI 0.48–0.95) after adjustment. Conclusions: Nearly half of those treated with methotrexate failed to complete follow-up. African-American women and multigravida women were at higher risk of being lost to follow up.
KW - Adherence
KW - Ectopic
KW - Methotrexate
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85108664006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108664006&partnerID=8YFLogxK
U2 - 10.1016/j.jogoh.2021.102180
DO - 10.1016/j.jogoh.2021.102180
M3 - Article
C2 - 34107357
AN - SCOPUS:85108664006
SN - 0368-2315
VL - 50
JO - Journal of Gynecology Obstetrics and Human Reproduction
JF - Journal of Gynecology Obstetrics and Human Reproduction
IS - 9
M1 - 102180
ER -